Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Psychedelics for the Treatment of Depression and Psychiatric Disorders

WEBINAR

Only

Psychedelics for the Treatment of Depression and Psychiatric Disorders

Tuesday, May 25, 2021, 7:00 PM - 8:30 PM EDT

Webinar

Presented By

The New York Academy of Sciences

 

Currently the FDA categorizes psychedelics such as LSD and psilocybin as Schedule I drugs, indicating that these substances have no medical benefits. Despite this classification, a resurgence of research has demonstrated therapeutic benefits of psychedelics for treatment of psychiatric disorders. These exciting findings have resulted in a paradigm shift for treatment-resistant psychiatric conditions, along with increased public interest and efforts to legalize psychedelics for medicinal use. This virtual conversation will bring together leading scientists in the fields of pharmacology, neuroscience, and psychiatry to discuss how psychedelics work in the brain to produce therapeutic benefits for depression and other mood disorders.  The role of psychotherapy in tandem with the psychedelic experience will also be explored.

Registration

Member
$15
Nonmember
$35
Nonmember Student, Undergrad, Grad, Fellow
$35
Member Student, Post-Doc, Fellow
$15

Moderator

John Krystal, MD
John Krystal, MD

Yale School of Medicine

Panelists

David E. Nichols, PhD
David E. Nichols, PhD

Heffter Research Institute

Roland Griffiths
Roland Griffiths, PhD

Johns Hopkins University School of Medicine

Rachel Yehuda, PhD
Rachel Yehuda, PhD

Icahn School of Medicine at Mt. Sinai

Event Sponsors